Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients

Trial Profile

Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 May 2018

At a glance

  • Drugs Ambrisentan (Primary)
  • Indications Congenital heart defects
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 May 2018 Planned End Date changed from 1 Jun 2018 to 1 Jul 2019.
    • 09 May 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top